Administration of Carboplatin for the urothelial carcinoma patients with impaired renal functio
Not Applicable
- Conditions
- rothelial carcinoma
- Registration Number
- JPRN-UMIN000014057
- Lead Sponsor
- The University of Tokyo Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1. patients with severe bone marrow suppression 2. patients with allergy to any platinum agents including Carboplatin, or Gemcitabine 3. patients during Pregnancy or Lactation, and with the hope of pregnancy 4. patients with severe liver dysfunction 5. patients with severe / uncontrollable infection 6. patients with active Chicken pox infection 7. patients with interstitial pneumonia and pulmonary fibrosis 8 patients who underwent radiation therapy for lung 9. Patients who progressed during prior chemotherapy using Gemcitabine/Carboplatin or Gemcitabine/CDDP 10. Otherwise, patients who are judged to be not eligible by attending doctors.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Adverse events / side effects including renal impairment
- Secondary Outcome Measures
Name Time Method Progression-free survival Response rate based on the RECIST criteria